An algorithm for differentiating food antigen-related gastrointestinal symptoms
Gastroenterology and Hepatology from Bed to Bench,
Vol. 14 No. 1 (2021),
26 January 2021
,
Page 8-16
https://doi.org/10.22037/ghfbb.v14i1.2238
Abstract
Background: A large number of food related gastro-intestinal disorders have been attributed to Irritable Bowel Syndrome (IBS) for decades. Discovery of food sensitivities and a high rate of symptomatic response to a low FODMAP diet (fermentable oligo-, di-, monosaccharides and polyols) has revolutionized the
Aim: The aim of this clinical audit was to assess patient-reported outcomes on the effect of dietary intervention, to enhance our understanding of possible treatment options in irritable bowel syndrome (IBS).
Background: A large number of food-related gastro-intestinal disorders have been attributed to IBS for decades.
Methods: Patient-reported outcomes from the records of 149 IBS patients treated at secondary and tertiary Gastroenterology outpatients in two UK hospitals between January 2014 and July 2016 were audited. Patients all presented with symptoms fulfilling Rome III-IV criteria for IBS had negative coeliac serology and did not have other gastrointestinal (GI) conditions. A modified version of a low FODMAP diet had been recommended (gluten and lactose free diet (G/LFD)) and was implemented for 6 weeks. Outcomes and dietary adherence were recorded during outpatient’s consultations.
Results: A total of 134 patients complied with the diet optimally. The majority had an improvement rate >70% and continued with the diet. Fifty-three percent became completely or almost asymptomatic, while 27.6% had a poor response to the diet (scoring < 30%) to G/LFD. The improvement was excellent in patients with normal BMI and good in overweight and obese and where BMI <18. Over 50% did not require any follow-up within 12 months.
Conclusion: Although it is unclear whether symptoms are triggered by gluten, fructans or lactose, elimination of gluten and lactose proved to be an effective treatment in patients with IBS. Multidisciplinary team management and implementation of detailed nutrition therapy using the audit algorithm might prove to be both cost effective and efficacious a treatment option in IBS.
Keywords: NCGS, Gluten, Fructans, Amylase trypsin inhibitors, FODMAP, Lactose intolerance, Irritable bowel syndrome.
(Please cite as: Rostami K, Bold J, Ali JE, Parr A, Dieterich W, Zopf Y, et al. An algorithm for differentiating food antigen-related gastrointestinal symptoms. Gastroenterol Hepatol Bed Bench 2021;14(1):8-16).
treatment of IBS. The aim of this clinical audit was to assess patient reported outcomes on the effect of dietary intervention in managing this group of patients to enhance our understanding of possible treatment options in IBS. Methods: Patient reported outcomes from the records of 149 IBS patients treated at secondary and tertiary Gastroenterology outpatients in two UK hospitals between January 2014 and July 2016 were audited. Patients all presented with symptoms fulfilling Rome III-IV criteria for IBS, had negative coeliac serology and did not have other gastrointestinal(GI) conditions. A modified version of a low FODMAP diet had been recommended (gluten and lactose free diet (G/LFD)) and was implemented for 6 weeks. Outcomes and dietary adherence were recorded during outpatient’s consultations. Out of 149 patients records, there was complete data for 134 patients. Results: 134 patients complied with the diet optimally. Ages ranged from 8 to 85 years, with mean age of 46.41± 17.388 years. Patients were predominantly female 109 (81.34%) in comparison to male 25 (18.66%). The majority had an improvement rate >70% and continued with the diet. 53% became completely or almost asymptomatic, while 27.6% had a poor response to the diet (scoring < 30%) to G/LFD. The improvement was excellent in patients with normal BMI and good in overweight, obese and where BMI <18. Over 50% didn’t require any follow-up within 12 months. Conclusions: Although, it is unclear whether symptoms are triggered by gluten, fructans or lactose, the elimination of gluten and lactose proved to be an effective treatment in these patients with IBS. Multidisciplinary team management and implementation of detailed nutrition therapy using the algorithm developed as a result of this audit might prove to be both a cost effective and efficacious treatment option in IBS, that is also easier for patients to implement than a full FODMAP exclusion and so is an area recommended for further research.
Keywords: Non-coeliac gluten sensitivity (NCGS), gluten, fructans, amylase trypsin inhibitors, FODMAP, lactose intolerance, irritable bowel syndrome
- : Non-coeliac gluten sensitivity (NCGS), gluten, fructans, amylase trypsin inhibitors, FODMAP, lactose intolerance, irritable bowel syndrome
How to Cite
References
Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-4.
Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology 2016;150:1393-407.
Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology 2016;150:1257-61.
Creed F. Review article: the incidence and risk factors for irritable bowel syndrome in population-based studies. Aliment Pharmacol Ther 2019;50:507-16.
Gibson PR, Shepherd SJ. Personal view: food for thought--western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005;21:1399-409.
Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 2015;149:1399-407.
Staudacher HM, Ralph FSE, Irving PM, Whelan K, Lomer MCE. Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet. J Acad Nutr Diet 2020;120:535-47.
Staudacher HM, Whelan K. The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS. Gut 2017;66:1517-27.
Kamal A, Pimentel M. Influence of Dietary Restriction on Irritable Bowel Syndrome. Am J Gastroenterol 2019;114:212-20.
Soubieres A, Wilson P, Poullis A, Wilkins J, France M. Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service. Front Gastroenterol 2015;6:246-51.
Biesiekierski JR, Newnham ED, Irving PM, Barrett JS, Haines M, Doecke JD, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol 2011;106:508-14.
Vazquez-Roque MI, Camilleri M, Smyrk T, Murray JA, Marietta E, O’Neill J, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology 2013;144:903-11.
Shahbazkhani B, Sadeghi A, Malekzadeh R, Khatavi F, Etemadi M, Kalantri E, et al. Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial. Nutrients 2015;7:4542-54.
Werlang ME, Palmer WC, Lacy BE. Irritable Bowel Syndrome and Dietary Interventions. Gastroenterol Hepatol 2019;15:16-26.
Yang J, Fox M, Cong Y, Chu H, Zheng X, Long Y, et al. Lactose intolerance in irritable bowel syndrome patients with diarrhoea: the roles of anxiety, activation of the innate mucosal immune system and visceral sensitivity. Aliment Pharmacol Ther 2014;39:302-11.
Catassi C, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, et al. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. Nutrients 2015;7:4966-77.
Carroccio A, Soresi M, D'Alcamo A, Fayer F, Carroccio A, et al. Risk of low bone mineral density and low body mass index in patients with non-celiac wheat-sensitivity: a prospective observation study. BMC Med 2014;12:230.
Jones J, Boorman J, Cann P, A Forbes, J Gomborone, K Heaton, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000;47:1-19.
Flik CE, Laan W, Smout AJ, Weusten BL, de Wit NJ. Comparison of medical costs generated by IBS patients in primary and secondary care in the Netherlands. BMC Gastroenterol 2015;15:168.
Brun-Strang C, Dapoigny M, Lafuma A, Wainsten JP, Fagnani F. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study. Eur J Gastroenterol Hepatol 2007;19:1097-103.
Catassi C, Alaedini A, Bojarski C, Bonaz B, Bouma G, Carroccio A, et al. The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update. Nutrients 2017;9.
Rej A, Trott N, Aziz I, Sanders DS. A Gluten-Free Diet: The Express Route to Fructan Reduction. Am J Gastroenterol 2019.
Busby E, Bold J, Fellows L, Rostami K. Mood Disorders and Gluten: It's Not All in Your Mind! A Systematic Review with Meta-Analysis. Nutrients 2018;10.
Godlee F. Gluten sensitivity: real or not? BMJ 2012;345:e8450.
Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988;48:1079-159.
Wang XJ, Camilleri M, Vanner S, Tuck C. Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to dietary restriction. Aliment Pharmacol Ther 2019;50:517-29.
Heydari F, Rostami-Nejad M, Moheb-Alian A, Mollahoseini MH, Rostami K, Pourhoseingholi MA, et al. Serum cytokines profile in treated celiac disease compared with non-celiac gluten sensitivity and control: a marker for differentiation. J Gastrointestin Liver Dis 2018;27:241-7.
Di Liberto D, Mansueto P, D'Alcamo A, Pizzo ML, Presti EL, Geraci G, et al. Predominance of Type 1 Innate Lymphoid Cells in the Rectal Mucosa of Patients With Non-Celiac Wheat Sensitivity: Reversal After a Wheat-Free Diet. Clin Transl Gastroenterol 2016;7:e178.
Uhde M, Ajamian M, Caio G, De Giorgio R, Indart A, Green PH, et al. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. Gut 2016;65:1930-7.
Bold J, Rostami K. Non-coeliac gluten sensitivity and reproductive disorders. Gastroenterol Hepatol Bed Bench 2015;8:294-7.
Rostami K, Aldulaimi D, Holmes G, Johnson MW, Robert M, Srivastava A, et al. Microscopic enteritis: Bucharest consensus. World J Gastroenterol 2015;21:2593-604.
Wu RL, Vazquez-Roque MI, Carlson P, Burton D, Grover M, Camilleri M, et al. Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. Lab Invest 2017;97:14-23.
Muir JG, Varney JE, Ajamian M, Gibson PR. Gluten-free and low-FODMAP sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical perspective. Int J Food Microbiol 2019;290:237-46.
Zevallos VF, Raker V, Tenzer S, Jimenez-Calvente C, Ashfaq-Khan M, Rüssel N, et al. Nutritional Wheat Amylase-Trypsin Inhibitors Promote Intestinal Inflammation via Activation of Myeloid Cells. Gastroenterology 2017;152:1100-13.
Zopf Y, Reljic D, Dieterich W. Dietary Effects on Microbiota-New Trends with Gluten-Free or Paleo Diet. Med Sci 2018;6.
Rostami K, Rostami-Nejad M, Al Dulaimi D. Post gastroenteritis gluten intolerance. Gastroenterol Hepatol Bed Bench 2015;8:66-70.
Tang I, MacFaul G, Madhotra R, Rostami K. Post pancreatitis/cholecystectomy gluten intolerance. Gastroenterol Hepatol Bed Bench 2018;11:273-5.
Casella G, Villanacci V, Di Bella C, Bassotti G, Bold J, Rostami K. Non celiac gluten sensitivity and diagnostic challenges. Gastroenterol Hepatol Bed Bench 2018;11:197-202.
Rostami K, Bold J, Parr A, Johnson MW. Gluten-Free Diet Indications, Safety, Quality, Labels, and Challenges. Nutrients 2017;9: 846.
- Abstract Viewed: 60 times
- PDF Downloaded: 35 times